Results 31 to 40 of about 30,645 (194)

Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment

open access: yesVirology Journal, 2021
Background Serum hepatitis B virus RNA (HBV RNA) has been reported to be a surrogate marker of intrahepatic cccDNA during nucleos(t)ide analogs therapy.
Xiaomei Wang   +10 more
doaj   +1 more source

Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting

open access: yesBrazilian Journal of Infectious Diseases, 2017
Aims: To evaluate the HBeAg seroconversion rate in real clinical setting and explore its predictors in long-term nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B (CHB).
Weiyan Yu   +12 more
doaj   +1 more source

Levels of HBV DNA and not HBsAg are associated with biochemical flares after HBeAg seroconversion [PDF]

open access: yes, 2012
BACKGROUND: The role of HBsAg levels in predicting subsequent flares in chronic hepatitis B patients after HBeAg seroconversion is not known METHODS: Serum HBsAg and HBV DNA levels were determined in 224 CHB patients at 6-12 months after spontaneous ...
Fung, J   +4 more
core   +1 more source

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy

open access: yesFrontiers in Medicine, 2022
BackgroundTissue covalently closed circular DNA (cccDNA) can reflect the activity of HBV replication. However, it is impractical to assess intrahepatic cccDNA in every outpatient.
Yachao Tao   +18 more
doaj   +1 more source

Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion

open access: yes, 2019
Hepatitis B virus (HBV) integration into the host cell genome occurs early on in infection and reportedly induces pro-oncogenic changes in hepatocytes that drive HCC initiation.
Thomas Tu (606295)   +3 more
core   +1 more source

Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients

open access: yesAnnals of Hepatology, 2017
Purpose: This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and
Xin Luo   +4 more
doaj   +1 more source

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α

open access: yes, 2014
Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBeAg-positive chronic hepatitis B (CHB) and explore whether liver histopathological features and other factors might influence HBeAg seroconversion.
Cheng-liang Zhu   +4 more
core   +1 more source

Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients

open access: yesInternational Journal of Infectious Diseases, 2016
Objectives: To assess off-treatment virological relapse rates and to determine the role of hepatitis B surface antigen (HBsAg) quantification in predicting virological relapse after stopping entecavir (ETV) treatment in patients with hepatitis B e ...
Yuan-wang Qiu   +11 more
doaj   +1 more source

Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs

open access: yesLipids in Health and Disease, 2021
Background The prevalence of dyslipidemia in China is increasing annually. Current studies suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies, while recent studies suggest that serum lipids influence the ...
Ziqiang Xia   +6 more
doaj   +1 more source

Spontaneous and 3-, 4-, and 5-year NA treatment-induced HBeAg seroconversion in HBeAg-positive CHB patients.

open access: yes, 2017
Spontaneous and 3-, 4-, and 5-year NA treatment-induced HBeAg seroconversion in HBeAg-positive CHB patients.
Lin Cao (294505)   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy